Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in Advanced Cancers With FGFR and Other Genomic Alterations
NCT02272998Phase 2Completed
- Start
- Feb 2015
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in solid tumor, hematologic malignancy. Started Feb 2015; status: completed.
02
Drugs
ponatinib
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT02272998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272998.